Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with Kronos Bio, Inc., to perform sequencing analysis for patients enrolled in Kronos Bio’s Phase 1/2 clinical trial of KB-0742, the company’s investigational CDK9 inhibitor. Tempus will use its xT broad-panel genomic assay to provide retrospective sequenc...
Tempus, a leader in precision medicine and artificial intelligence, today announced its collaboration with Precision Health Informatics, a wholly-owned subsidiary of community-based cancer care pioneer Texas Oncology, to accelerate the advancement of precision medicine in oncology. This collaboration aims to further precision medicine research through unique insights derived from Pre...
Tempus, a leader in artificial intelligence and precision medicine, today announced a strategic collaboration to develop a companion diagnostic (CDx) test with A2 Biotherapeutics for its new therapy targeting patients with Loss of Heterozygosity (LOH). It is anticipated that this collaboration could also provide a platform for the...
Bayer and Tempus, leaders in precision medicine and artificial intelligence (AI), announced a new collaboration designed to provide broader access to genomic testing and tailored treatment approaches for the oncology community. The collaboration will include an initiative to help facilitate patient identification for precision oncology by providing testing, via the Te...
Tempus, a leader in artificial intelligence and precision medicine, today announced that it has CE marked its signature broad-panel genomic sequencing assay, xT. The CE marked xT test is now available for clinical use in Europe. As part of Tempus’ broader regulatory strategy, European clinicians and their patients...
Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced that Christopher Mason, PhD, has joined as the Vice President of Emerging Genome Technology. Dr. Mason has been a pioneer in next-generation sequencing (NGS) diagnostics, multi-omic approaches to modeling disease,...
Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announces its study, along with a collaborative research initiative to expedite project needs during the COVID-19 pandemic. Many oncology research projects have been delayed as building the necessary datasets are difficult...
Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, announced the launch of two new oncology tests designed to equip physicians with even more precise genomic data in an effort to improve therapeutic outcomes. Tempus|HRD, a test that identifies a...
Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, has reached a milestone in fully enrolling 2,500 oncologists into its Tempus Integrated Molecular Evaluation (TIME) Trial™ Program that seeks to rapidly match patients largely in the community setting to targeted clinical trials....
Rush University Medical Center is the first health care organization to launch medical record company Epic’s module for genomic results, giving providers the tools they need to tailor patient care at the molecular level. Rush will use the module as part of its Precision Oncology Center to...
